← Back to Clinical Trials
Recruiting NCT07341256

NCT07341256 Father-Focused Breastfeeding Education and Breastfeeding Outcomes

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07341256
Status Recruiting
Phase
Sponsor Timuçin İmdadoğlu
Condition Breastfeeding
Study Type INTERVENTIONAL
Enrollment 240 participants
Start Date 2026-01-03
Primary Completion 2026-08-15

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Father-Focused Breastfeeding Education

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 240 participants in total. It began in 2026-01-03 with a primary completion date of 2026-08-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Breastfeeding is recommended as the optimal feeding method for infants during the first six months of life. Support from fathers or partners plays an important role in initiating and maintaining breastfeeding. However, most breastfeeding education programs mainly focus on mothers, and structured education directed to fathers is limited. This study aims to evaluate the effect of a short, structured, father-focused breastfeeding education given shortly after birth on paternal support behaviors and breastfeeding outcomes. Fathers of healthy term newborns will be randomly assigned to receive either a brief breastfeeding support education or routine care. Paternal support behaviors will be assessed using a validated questionnaire, and infant feeding outcomes will be evaluated during follow-up. The results of this study may help improve breastfeeding support strategies by involving fathers more actively in the early postnatal period.

Eligibility Criteria

Inclusion Criteria: * Fathers or partners aged 18 years or older. * Fathers or partners of healthy term newborns (≥37 weeks gestation). * Newborns without major congenital anomalies or chronic medical conditions. * Fathers or partners present during the early postnatal period. * Ability to understand and communicate in Turkish. * Provision of written informed consent. Exclusion Criteria: * Fathers or partners of preterm infants (\<37 weeks gestation). * Newborns requiring neonatal intensive care unit admission. * Newborns with major congenital anomalies or severe medical conditions. * Fathers or partners unable to complete follow-up assessments. * Refusal or inability to provide informed consent.

Contact & Investigator

Central Contact

timucin imdadoglu, MD

✉ dr.timucini@gmail.com

📞 +90 535 742 6892

Principal Investigator

timucin imdadoglu, MD

PRINCIPAL INVESTIGATOR

University of Health Sciences Turkey, Sancaktepe Prof. Dr. Ilhan Varank Training and Research Hospital

Frequently Asked Questions

Who can join the NCT07341256 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Breastfeeding. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07341256 currently recruiting?

Yes, NCT07341256 is actively recruiting participants. Contact the research team at dr.timucini@gmail.com for enrollment information.

Where is the NCT07341256 trial being conducted?

This trial is being conducted at Istanbul, Turkey (Türkiye).

Who is sponsoring the NCT07341256 clinical trial?

NCT07341256 is sponsored by Timuçin İmdadoğlu. The principal investigator is timucin imdadoglu, MD at University of Health Sciences Turkey, Sancaktepe Prof. Dr. Ilhan Varank Training and Research Hospital. The trial plans to enroll 240 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology